Phase 1/2 trial: you would not believe, CRB-701, a Nectin-4 ADC!

[Maxone73]

Ok...and it's 3 for today!

CRB-701 (SYS6002) is an investigational antibody-drug conjugate (ADC) targeting Nectin-4, a protein overexpressed in various cancers.

CRB-701 combines a monoclonal antibody with a cytotoxic agent, aiming to deliver targeted therapy to cancer cells while minimizing damage to healthy tissues.

In a Phase 1 dose-escalation study, CRB-701 demonstrated promising results. At doses of 2.7 mg/kg or higher, the overall response rate was 43%, with a disease control rate of 71%. Notably, no dose-limiting toxicities were observed up to 4.5 mg/kg, and adverse events were primarily mild to moderate, including manageable skin rash and neuropathy.

These findings suggest that CRB-701 is well-tolerated and exhibits anti-tumor activity in patients with Nectin-4-positive solid tumors.

prostatewarriors.com/2025/0...

[MikeMartin]

I think that Nectin-4 is expressed in certain prostate cancer tissues, its prevalence and significance remain variable. you need to be tested for it. The trial results seem to focus more on other cancer types

[Maxone73 in reply to MikeMartin]

It's a debate, there are different results from different studies, but yes, I think that they would test you beforehand in case of prostate cancer (as they did with enfortumab vedotin I think).